Wave Life Sciences Ltd. Stock News

WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s

This stock currently has a good balance of risk and potential rewards.

Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space.

Wave Life Sciences Ltd. NASDAQ: WVE is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.

Wave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration of 200 mg of WVE-006 resulted in the presence of wild-type alpha-1 antitrypsin protein; This led to a more than 60% increase of AAT. The global Alpha-1 Antitrypsin Deficiency market is expected to...

Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.

Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data...

24/7 Wall St. Insights Public offerings of stock and activist investor activity have prompted some huge insider buying.